Literature DB >> 11176399

Biochemical recurrence after radical prostatectomy in black and white American men with a positive or negative family history of prostate cancer.

V Narain1, R Tiguert, M Banerjee, D Grignon, D P Wood, I J Powell.   

Abstract

PURPOSE: We investigated the impact of a family history of prostate cancer on predicting biochemical recurrence in black and white American men.
MATERIAL AND METHODS: Between January 1991 and December 1996, 910 men underwent radical retropubic prostatectomy for clinically localized prostate cancer, of whom 676 had data available on prostate cancer family history. Statistical analysis was performed to identify any correlation among the known predictors of biochemical outcome and family history in each race.
RESULTS: Median followup was 34 months (range 2 to 103). We identified 355 (52%) and 321 (48%) white and black American men, respectively, for whom data were available on prostate cancer family history, including 177 (26%) with a positive and 499 (74%) with a negative history. Family history was positive in 94 black (29%) and 83 white (23%) men. No significant difference was noted in the incidence of familial prostate cancer in the 2 races (p = 0.10). In black men the biochemical failure rate was 32% and 26% in those with a positive and negative history (log rank test p = 0.51), while in white men the rate was 17% and 18%, respectively (log rank test p = 0.79). A family history positive for prostate cancer was not associated with biochemical failure in either race.
CONCLUSIONS: Biochemical recurrence was not significantly worse in patients with a family history of prostate cancer than in those with nonfamilial disease in either race.

Entities:  

Mesh:

Year:  2001        PMID: 11176399     DOI: 10.1097/00005392-200102000-00028

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  1 in total

1.  Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer.

Authors:  Matthew H Hayn; Heather Orom; Vickie L Shavers; Martin G Sanda; Mark Glasgow; James L Mohler; Willie Underwood
Journal:  Cancer       Date:  2011-03-31       Impact factor: 6.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.